10
Participants
Start Date
October 31, 2014
Primary Completion Date
February 14, 2017
Study Completion Date
February 14, 2017
Treatment simplification
Eligible, consenting subjects will start open-label darunavir 800mg plus the co-formulated tenofovir DF/FTC/cobicistat/elvitegravir (Stribild) tablet once daily with food, following the study procedures at the baseline visit. They will be assessed at weeks 2, 12, 24, 36, and 48 after starting the new regimen.
St. Paul's Hospital Immunodeficiency Clinic, Vancouver
Collaborators (1)
Gilead Sciences
INDUSTRY
University of British Columbia
OTHER